Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 9/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204126 | 0.86 | KCNN4 (0.57) | KCNN4NPSR1P2RX7ALDH1A1MAPT | |
| SCHEMBL4215231 | 0.86 | KCNN4 (0.42) | KCNN4NPSR1P2RX7ALDH1A1MAPK1 | |
| SCHEMBL4209251 | 0.83 | KCNN4 (0.55) | KCNN4NPSR1P2RX7ALDH1A1ADRA1D | |
| SCHEMBL4207466 | 0.82 | KCNN4 (0.41) | KCNN4NPSR1P2RX7ALDH1A1MAPT | |
| SCHEMBL4210039 | 0.82 | ALDH1A1 (0.56) | KCNN4P2RX7ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4207470 | 0.81 | ALDH1A1 (0.44) | KCNN4NPSR1P2RX7ALDH1A1MAPK1 | |
| SCHEMBL4209298 | 0.80 | ALDH1A1 (0.48) | KCNN4P2RX7ALDH1A1MAPK1 | |
| SCHEMBL4208312 | 0.79 | KCNN4 (0.49) | KCNN4NPSR1P2RX7ALDH1A1ADRA1D | |
| SCHEMBL4209113 | 0.79 | ALDH1A1 (0.45) | KCNN4NPSR1P2RX7ALDH1A1MAPK1 | |
| SCHEMBL4209716 | 0.78 | KCNN4 (0.51) | KCNN4NPSR1P2RX7ALDH1A1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579480-B2 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2009-08-25 | — | — | US | disclosed |
| US-20070060630-A1 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1650198-A1 | ALKOXYTETRAZOL-1-YLBENZALDEHYDE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Toyo Kasei Kogyo Company Limited (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060630-A1 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | ALDH7A1, NAT1, ARSA | KCNN4 3193/4885NPSR1 2735/4885P2RX7 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.